Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 08, 2024

Amivantamab Plus Lazertinib for Previously Untreated EGFR-Mutated Advanced NSCLC

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
N. Engl. J. Med 2024 Jun 26;[EPub Ahead of Print], BC Cho, S Lu, E Felip, AI Spira, N Girard, JS Lee, SH Lee, Y Ostapenko, P Danchaivijitr, B Liu, A Alip, E Korbenfeld, J Mourão Dias, B Besse, KH Lee, H Xiong, SH How, Y Cheng, GC Chang, H Yoshioka, JC Yang, M Thomas, D Nguyen, SI Ou, S Mukhedkar, K Prabhash, M D'Arcangelo, J Alatorre-Alexander, JC Vázquez Limón, S Alves, D Stroyakovskiy, M Peregudova, MAN Şendur, O Yazici, R Califano, V Gutiérrez Calderón, F de Marinis, A Passaro, SW Kim, SM Gadgeel, J Xie, T Sun, M Martinez, M Ennis, E Fennema, M Daksh, D Millington, I Leconte, R Iwasawa, P Lorenzini, M Baig, S Shah, JM Bauml, SM Shreeve, S Sethi, RE Knoblauch, H Hayashi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading